Peptide/Protein Ingredients TRIZ Cases

Biodegradable nanoparticles target liver sinusoidal endothelial cells to deliver antigens and induce long-term immune tolerance.

Multiple peptide loops on an aromatic scaffold improve PD-L1 binding affinity, specificity, and stability for therapeutic conjugates.

Back-filled insulin segments and insulin-on-board calculations let automated dosing personalize basal rates and reduce manual recalibration burden.

By breaking down hyaluronic acid, hyaluronidase enables faster high-volume subcutaneous dosing with less pain, leakage, and swelling.

An EV membrane-coated MOF nanoparticle protects proteins from degradation, reduces phagocytosis, and enables pH-responsive targeted delivery.

Sub-nanomolar TPA antibodies block fibrin-dependent plasminogen activation to reduce systemic and brain hemorrhage after thrombolytic therapy.

Apelin restores lymphatic pumping and limits fibrosis in lymphedema, helping reduce limb swelling and improve lymphatic density.

Classifying fast and slow acetylators guides 3,4-DAP dosing and food timing to stabilize exposure, improve symptom control, and limit adverse events.

rAAV vectors deliver functional PCCA or PCCB genes to address the enzyme deficiency in propionic acidemia and reduce lifelong treatment burden.

A lipid-polymer microsphere depot suppresses initial drug burst while improving suspensibility and continuous release after reconstitution.

Modified retinal-targeting rAAV delivery restores cone photoreceptor function while balancing transduction efficiency and dosing safety.

Micronized porcine collagen with PHMB conforms to tunnelling wounds, contacts the wound bed directly, and helps control bacterial colonization.

Umami amino acids, milk proteins, and nucleotides make drinking water more palatable to cats, increasing hydration to help prevent CKD and urinary disease.

A single intravitreal rAAV dose drives sustained anti-C3 antibody expression in the eye to slow geographic atrophy without repeated injections.

Targeted AAV3B capsid substitutions improve hepatocyte transduction while reducing neutralization by pre-existing antibodies.

Localized cytokine delivery from biocompatible cell-encapsulated implants supports heart and lung repair while reducing immune rejection.

GPC-3-binding antibodies and CAR designs improve HCC targeting by inducing ADCC and T-cell activation against tumor cells.

Autologous adipose extract and 3D-molded sheet geometry speed diabetic foot ulcer treatment while preserving skin regeneration activity.

Cationic CTX-1-derived peptides balance broad-spectrum antimicrobial action with low eukaryotic toxicity and stability in high-salt conditions.

Pseudouridine and m1Ψ RNA modifications cut dendritic-cell cytokine secretion while preserving in vitro protein expression.

A dual GLP-1/GLP-2 agonist composition improves long-term diarrhea control after bowel resection by reducing stool frequency, water content, and urgency.

A benzyl-type GAP protecting group enables solution-phase peptide synthesis with selective precipitation, avoiding chromatography and polymer supports.

Selective FAP-binding cyclic polypeptides improve tumor uptake and retention, helping diagnose and treat FAP-mediated tumors with fewer off-target effects.

Combining IL-2 with antibody immunotherapy restores immune recognition and rejection of tumors that evade MHC-I or IFN signaling.

Amotosalen and UVA treatment lets cryoprecipitate remain usable up to 168 hours after thawing while maintaining safety and fibrinogen consistency.

Magnetic nanoparticle-loaded nasal septum chondrocytes form mobile spheroids that improve cartilage repair while lowering nanoparticle exposure.

Targeted CRISPR-Cas9 editing corrects the USH2A 2299 guanine deletion to help delay vision and hearing loss in Usher syndrome and retinitis pigmentosa.

SCGB preparations bind HSPGs in the glycocalyx to prevent shedding, maintain vascular barrier integrity, and limit tissue damage.

Pre-AAV CD19 inhibition suppresses humoral immunity, improves transgene expression, and enables redosing despite neutralizing antibodies.

Controlled hyaluronidase-assisted injection reduces tissue resistance, back leakage, swelling, and pain during high-volume subcutaneous dosing.

A controlled-release CNP agonist extends release beyond 6 hours to reduce hypotension and support higher-dose treatment efficacy.

Binding agents against exosome proteins clear extracellular vesicles to disrupt metastasis despite tumor heterogeneity and therapy resistance.

Engineered fibroblasts target bone remodeling imbalance by inhibiting RANK ligand, reducing osteoclast activity, and stimulating osteoblasts.

PEI-linked protein conjugates improve endosomal escape and cytoplasmic target binding while remaining stable in blood and serum.

An ex vivo hematoma scaffold mimics fracture clots to speed large bone defect repair while lowering BMP-2 dose and side effects.

Specific peptides suppress IL-17 and ROR gammaT to ease Behcet's skin ulcers and rheumatoid arthritis with fewer side effects.

Engineered polypeptides degrade immunogenic gluten peptides at pH 4, enabling oral celiac sprue treatment in the stomach.

Combining phorbol esters with G-CSF or EPO boosts neutrophils, platelets, and hemoglobin to shorten chemotherapy-induced cytopenia.

Non-natural amino acid linkers improve plasma stability and half-life while enabling selective tumor-site cleavage in cancer drug conjugates.

Adding calcium or barium ions to the polycation coating liquid helps form uniform cell microcapsules with more stable immunoisolation.

Topical delivery of at least three cytokines disrupts the tumor microenvironment, activates innate and adaptive immunity, and helps prevent recurrence.

S-derived scFv in BCMA CAR-T cells improves myeloma cell killing and tumor elimination while helping address recurrence after current therapies.

Weekly IL-17A and albumin binding fusion protein dosing extends half-life, improves tissue penetration, and reduces ankylosing spondylitis inflammation.

Engineered cysteine protease variants improve thermal stability and IgG-cleaving potency to lower pathogenic antibodies in transplantation and gene therapy.

Customized penalty ratios in a closed-loop artificial pancreas balance glucose and insulin excursions to reduce hypoglycemia and hyperglycemia.

Glatiramer acetate is combined with immune checkpoint inhibitors to reactivate dysfunctional CD8+ T cells and improve tumor control.

Selective IL-2 amino acid substitutions reduce IL-2Rα binding while preserving β/γc affinity, boosting anti-tumor immunity with less immunosuppression.

A reduced thioredoxin-active peptide breaks mucus disulfide bonds to lower viscosity with greater stability and longer therapeutic effect.

Amino acid-modified IdeZ polypeptides improve human IgG1 and IgG2 cleavage while lowering immunogenicity and dose burden.

Direct powder compression with optimized excipients improves low-dose allergen tablet uniformity, stability, and rapid sublingual disintegration.